← All trials
NCT05558319
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Apr 30, 2027
- Completion date
- Apr 30, 2029
- First posted
- Sep 28, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 480
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PETHEMA FoundationLead sponsor
- Adknoma Health ResearchCollaborator
- University of NavarraStudy chair
- University of BarcelonaStudy chair
- University of SalamancaStudy chair
- Universidad Complutense de MadridStudy chair
- University of CantabriaStudy chair
- SanofiCollaborator
- University of SalamancaOfficial
- University of BarcelonaOfficial
- University of NavarraOfficial
- University of CantabriaOfficial
- Bristol-Myers SquibbCollaborator
- Universidad Complutense de MadridOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.